Background: There is limited data on the impact of calcium (Ca) on acute procedural and clinical outcomes in patients with lesions treated with bioresorbable vascular scaffolds (BRS). We sought to evaluate the effect of calcium on procedural and clinical outcomes in a 'real world' population. Methods: Clinical outcomes were compared between patients with at least 1 moderately or heavily calcified lesion (Ca) and patients with no/mild calcified lesions (non-Ca) enrolled in our institutional BRS registry. Overall device success rate was 99.1% with no significant differences between the groups. Despite more aggressive lesion preparation and postdilation compared to non Ca, acute lumen gain was significantly less in Ca lesions (1.50 ± 0.66 vs 1.62 ± 0.69 mm, p = 0.040) with lower final MLD (2.28 ± 0.41 vs 2.36 ± 0.43, p = 0.046). There were no significant differences in all-cause mortality, total definite scaffold thrombosis (ST), target lesion revascularization and myocardial infarction between the 2 groups. Late ST was more frequent in the Ca group compared to non Ca group (late ST: 2.1 vs 0%, p = 0.02). Conclusions: Clinical outcomes after BRS implantation in calcified and non-calcified lesions were similar. A remarkable difference in timing of thrombosis was observed, with an increased rate of late thrombosis in calcified lesions.
Bioresorbable scaffolds (BRS) have been developed as an alternative to metallic stents as the need for mechanical support for the treated vessel is temporary, and beyond the first few months there are potential disadvantages of a permanent metallic prosthesis. In earlier studies to demonstrate Absorb BRS feasibility and safety, severe calcification was an exclusion criterium [1] [2] [3] [4] [5] [6] . Calcified lesions may be challenging and encountered in up to 35% of patients who undergo percutaneous coronary intervention (PCI) [7] [8] . Lesion calcification has been associated with increased PCI complexity with worse procedural outcomes compared to non-calcified lesions [9] . Wire crossing, delivery of equipment during pre and post dilation and stent delivery may be more cumbersome. In calcific lesions, the effect of acute plaque recoil may affect stent expansion and is associated with adverse clinical and angiographic outcomes [10] [11] . Currently there is still limited data on the impact of calcium (Ca) on acute procedural and clinical outcomes in patients with lesions treated with BRS. We sought to determine the impact of calcification on acute angiographic and 2 year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold (BVS) system (Abbott Vascular, Santa Clara, CA, USA).
Ethics
This is an observational study, performed according to the privacy policy of the Erasmus MC, and to the Erasmus MC regulations for the appropriate use of data in patient-oriented research, which are based on international regulations, including the declaration of Helsinki. Approval of the ethical board of the Erasmus MC was obtained. All patients undergoing clinical follow-up provided written informed consent for the PCI and to be contacted regularly during the follow-up period of the study.
Quantitative Coronary Analysis (QCA)
The angiographic analysis was performed by three independent investigators. Coronary angiograms were analyzed with the CAAS 5.10 QCA software (Pie Medical BV, Maastricht, the Netherlands). The QCA (Quantitative Coronary Analysis) measurements provided reference vessel diameter (RVD), percentage diameter stenosis and minimal lumen diameter (MLD). Acute gain was defined as post-procedural MLD minus pre-procedural MLD (in an occluded vessel MLD value was zero by default).
Angiographic assessment of lesion calcification
Lesion calcification was recognized as radio-opacities within the vessel wall at the treated lesion. Calcification was categorized as either none/mild or moderate if the radio-opacities were noted only during the cardiac cycle before contrast injection and further classified as either none/mild or moderate based on visual assessment. Severe calcification was defined as having multiple persisting (that are noted even without cardiac motion) opacifications of the coronary wall and visible in more than one projection, surrounding the complete lumen of the coronary artery at the site of the lesion as per SYNTAX definition (www.syntaxscore.com). Angiographic assessment of calcification was conducted independently by 2 cardiologists. In cases of disagreement, a third independent cardiologist reviewed the films and provided a final diagnosis.
Follow-up
Clinical demographic data of all patients were obtained from municipal civil registries. Follow-up information specific for hospitalization and cardiovascular events was obtained through questionnaires. If needed, medical records or discharge letters from other hospitals were requested. Events were adjudicated by an independent clinical events committee (CEC). All information concerning baseline characteristics and follow-up was gathered in a clinical data management system. Only patients who had given written consent for follow up were included in the clinical outcome assessments.
Definitions
The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite endpoint of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR). The secondary endpoints were device oriented composite endpoints (DOCE: composite of cardiac death, target vessel myocardial infarct and clinically indicated target lesion revascularization) and patient oriented composite endpoints (POCE: composite of all-cause mortality, all-cause myocardial infarct and any revascularization). Deaths were considered cardiac unless a non-cardiac cause was definitely identified. TLR was described as any repeated revascularization of the target lesion. Target vessel revascularization (TVR) was defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. Non-target vessel revascularization was described as any revascularization in a vessel other than the target lesion. Scaffold thrombosis (ST) and MI were classified according to the Academic Research Consortium (ARC) [14] . Clinical device success was defined as successful delivery and deployment of the first study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of b30% as evaluated by QCA. Clinical procedure success was described as device success without major peri-procedural complications or in-hospital MACE (maximum of 7 days).
Statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as mean ± standard deviation. The cumulative incidence of adverse events was estimated according to the Kaplan-Meier method. Patients lost to follow-up were considered at risk until the date of last contact, at which point they were censored. A cox regression was performed to investigate clinical outcomes at two years, with the binary variable calcification (yes/no). Adjusted cox regression were performed using fourteen patient and lesion factors (see Online Supplement Table 1 ) to account for baseline differences between patients with at least 1 moderately or heavily calcified lesion (Ca) and patients with no/mild calcified lesions (non-Ca). Statistical analyses were performed using SPSS, version 21 (IL, US). All statistical tests were two-sided and the p value of b0.05 was considered statistically significant.
Results
Baseline clinical characteristics are shown in Table 1A . A total of 548 lesions in 455 patients were studied of which 200 (36.5%) lesions in 160 patients (35.2%) were moderately or heavily calcified (Ca group) (Table 1A) . Patients in the Ca group were older, with more hypertension, and kidney disease. In the calcified cohort, there were 1.24 lesions per patient. Lesion and QCA characteristics are as shown in Table 1B . The left anterior descending artery (n = 254, 46.4%) was the most commonly treated vessel in the study population. Lesions in the Ca group were more complex (AHA B2/C lesion: 69.0% in Ca vs 14.9% in non-Ca, p b 0.001) and significantly longer. Compared to non-Ca group, lesions in the Ca groups had smaller RVD and lower percentage diameter stenosis.
Procedural characteristics are as shown in Table 1C . Ca lesions were treated with more aggressive lesion preparation compared to non Ca as evidenced by the more significant use of predilation, rotational atherectomy and scoring balloon. The use of buddy wires was higher in Ca lesions compared to non Ca lesions. Fig. 1A illustrates the satisfactory expansion with minimal eccentricity on OCT of a calcified LAD treated with a BRS. Fig. 1B and C illustrates the acute and 2 year angiographic and IVUS result respectively after rotational atherectomy and lesion preparation followed by BRS implantation in a calcified coronary artery. A total of 735 scaffolds were implanted in the study population with more scaffolds per lesion for Ca lesions (1.58 vs 1.21). Scaffold diameter was similar in the two groups however scaffold length implanted was longer in the Ca group. Postdilation was more frequently used in the Ca group (Ca vs non Ca: 64.8% vs 42.1%, p b 0.001).
Procedural outcomes are shown in Table 2A . Post procedure, acute lumen gain was significantly less in Ca compared to non-Ca lesions (1.50 ± 0.66 vs 1.62 ± 0.69 mm, p = 0.040) with lower final MLD (2.28 ± 0.41 vs 2.36 ± 0.43, p = 0.046). RVD and percentage diameter stenosis were smaller in the Ca group compared to the non Ca group though the differences did not reach statistical significance. Procedural success was high for both patient groups (98.7 and 99.7%, p = 0.25). Overall device success rate and final TIMI 3 flow result were similar in the two groups.
We were able to obtain written consent for the follow up program in 395 patients (86.8%). Clinical outcomes were available in all (100%) of these patients (Table 2B) . These patient had similar baseline and procedural characteristics as the total population. Kaplan-Meier curves for MACE were parallel throughout the follow-up to two year ( Fig. 2A) . Crude cumulative event rates at two years for the secondary endpoints, described as Kaplan-Meier estimates are as shown in Table 2B . There was a slight trend for higher events on cardiac death and all-cause mortality for patients with calcified lesions. No difference was observed in POCE and DOCE. Though definite ST rates were similar between the two groups ( Fig. 2B ), there was a remarkable variation in acute and late definite ST. For acute definite ST, the incidence was higher in the non-Ca lesions; for late definite ST there was a significant increase in Ca group compared to non-Ca group (late ST: 2.1% vs 0, p = 0.02) but not for very late ST (Table 2B) . After adjusting for difference in baseline characteristics, Ca lesions was not found to be a significant predictor of any clinical events (Table 2C ).
Discussion
In our study, the key finding was that despite Ca lesions were more complex, required more lesion preparation, and encountered more deliverability issues with lower acute luminal gain and smaller final MLD, acute procedural and 24 month clinical outcomes were similar regardless of the calcification group with the exception of a higher rate of late ST at 2 years in the Ca group compared to non-Ca group. While there have been earlier studies evaluating the use of BRS in calcified lesions. [15] [16] [17] , this is the first large clinical prospective registry study involving BRS scaffolds that look at the impact of lesion calcification on long term clinical outcomes at 2 years.
Our findings, which showed that Ca lesions were more complex and required more careful and elaborate lesion preparation including rotational atherectomy (in 5.5% of the lesions), were consistent with similar findings published elsewhere [9, 18] . The use of intracoronary imaging like IVUS was also increased in Ca lesions compared to non Ca lesions. The more frequent use of buddy wires in the Ca group suggested that difficult deliverability issues may be encountered more commonly in Ca lesions thus potentially prolonging procedure times. Despite the advances in interventional techniques, calcific lesions still pose a challenge for the procedurist. Due to their inherent polymeric structural composition and increased strut thickness, BRS have been shown to have less favorable mechanical characteristics including less deliverability and radial strength compared to current second generation DES [18, 19] . There have been concerns as to whether such mechanical characteristics may result in less optimal stent performance which may be more pronounced in calcified lesions where focal areas of calcification limit expansion of the BRS more compared to DES [18] . This may have practical clinical implications since suboptimal stent expansions has been known to contribute to metallic stent failure [20] and there have been reports of inadequate scaffold expansion in BRS failure [21, 22] .
Our findings are also consistent with clinical [23, 24] data addressing the feasibility of BRS in calcified lesions. In a recent study looking at specific procedural outcomes in 62 calcified lesions by Panoulas et al. [23] , expansion of BRS as measured in terms of lumen gain on QCA and intravascular ultrasound (IVUS) was similar between calcified and non-calcified lesions. Acute luminal gain (1.83 ± 0.6 vs 1.86 ± 0.6 mm, p = 0.732) and angiographic success were similar (98% non-calcific vs 95.2% calcific, p = 0.369), whereas procedural success was reduced in patients with calcific lesions (94.1% vs 83.9%, p = 0.034) due to higher rates of periprocedural myocardial infarction (MI) (5% vs 13.1%, p = 0.067). MACE rates (10.9% non-calcific vs 12.9% calcific, p log-rank = 0.546) were similar in the median follow-up time of 14 months. However a greater degree of lesion preparation in calcified lesions was also required. OCT was not used and a comparison of the expansion of BRS compared with DES was not performed. In our study, we report 2 year clinical outcomes in a larger study population which showed MACE rates were similar between Ca and non-Ca groups. In another study conducted by Kawamoto et al. [24] , though eccentric calcium distribution resulted in asymmetric expansion of BRS, the final MSA was still comparable irrespective of calcium distribution, and the use of IVUS for scaffold optimization led to favorable clinical outcomes even in calcified lesions. Earlier OCT findings published from our center [25] also suggest that regardless of the degree of angiographic calcification, BRS can achieve a similar expansion as DES, in the context of an imaging-guided strategy with adequate lesion preparation. Our findings were also consistent with recent published literature showing that the presence of moderate or severe lesion calcification does not negatively affect angiographic outcomes at both post-procedure and 13-month follow-up after BVS implantation [26] . However, in this study [26] , heavily calcified lesions or those requiring extensive lesion preparation such as rotational atherectomy were excluded according to the study protocol whereas our study included "all comers" lesions with various degrees of calcification or that require rotational atherectomy.
However, BRS deployment requires more lesion preparation and decalcification strategy particularly for moderately or heavily calcified lesions. Further studies are needed to ascertain if in such lesions the use of such a strategy may impact on long term clinical outcomes such as increased TLR rates such as seen in DES deployment after lesion debulking or decalcification using rotational atherectomy [27, 28] . In addition, the postdilation rate reported in our study (Table 1C) was comparable to other studies considering that systematic postdilation was implemented on average in b 50% of previously published studies [29] . It is still debatable if pursuing a systematic postdilation strategy will have an impact on long term results particularly the risk of very late ST (VLST). Given the results of this study, an analysis of BRS specific implantation technique such as PSP (Prepare the lesion to be reengineered; Size the vessel appropriately; Postdilate to embed scaffold struts into the vessel wall) would be timely and of interest [30] . Though the lesions treated in the Ca group were more complex, requiring longer and more overlapping scaffolds and the post dilatation rate of 64.8% was considered relatively low for calcific lesions, the procedural and clinical results were still similar between the Ca and non Ca groups. This may be reassuring since the current practice suggest a large use of postdilation especially in stable patients with complex lesions.
BRS offers several unique potential advantages over DES. The future bioresorption of BRS permits potential future grafting of treated segments, allows potential reopening of "jailed" side branches and potential recovery of vasomotor function and vessel remodeling. These benefits would be more pertinent in patients with calcific lesions, who often have widespread disease resulting in long stented segments. However whether these will translate into long term clinical benefits in more complex lesions such as those with significant calcifications would Values are expressed as numbers (percentages) or mean ± standard deviation when appropriate. still require further evaluation. Previous studies have highlighted a higher rate of ST related to the use of BRS [4, [31] [32] [33] , but did not provide details on the effect of calcification. In our study, we see an observation pattern of higher early ST cases in the non-Ca group followed by a significantly higher rate of late ST in the Ca group. To the best of our knowledge, we believe the difference in timing on ST observed in the two groups is notable and interesting which warrant further studies. The observation of early ST in the non-Ca group (a group with a higher number of acute coronary syndromes; ACS) patients might be related to scaffold under sizing and to increased platelets activation. Predisposing factors of scaffold undersizing include the increased thrombus burden and vasoconstriction in the setting of acute STEMI leading to underestimation of the actual size of the infarct-related artery, thus increasing the risk of the implantation of undersized scaffolds which can be seen even in the setting of metallic drug eluting stents [34] . Implantation of a relatively small scaffold in a relatively larger vessel can result in incomplete apposition, predisposing to ST [35] . Higher rates of ST were also previously noted in patients with ACS which could be due to reduction of early neointimal growth and strut coverage [36, 37] . Reasons for the increase in late ST in the Ca compared to the non Ca group include a role for technical factors such as suboptimal implantation with incomplete lesion coverage, underexpansion and malapposition [35, 38] and possibly greater impact on the scaffold endothelization and resorption process from a reduced MLD in the Ca group. The additional risks of late ST in the Ca lesions may arise from either the loss of radial strength after scaffold resorption (which typically commences 6 months to N1 year after scaffold implantation) or the scaffold 'dismantling' around calcified lesions which will have forces localized at the edge of the calcified areas where expansion tends to be asymmetrical [24] . Scaffold 'dismantling' might result in rapid changes in vessel wall architecture and therefore exert localized forces on the neointimal coverage potentially resulting in microdissections, triggering the thrombosis. In our current study, though the event rate is similar between the Ca and non Ca groups, this may also be partially attributed to a higher ACS population in the non Ca group which is known to have higher risk of clinical events at follow up. In an earlier study evaluating the one-year outcomes in patients presenting with ACS compared to stable angina patients after implantation of a BRS from our center, one-year clinical outcomes in ACS patients treated with BRS were similar to non-ACS patients. One-year definite ST rate was comparable: 2.0% for ACS population versus 2.1% for stable population (p = 0.94), however, early ST occurred only in ACS patients [39] . Comparatively, overall ST rates were similar between the two groups in this study and further analysis did not show that Ca lesions were a significant predictor of ST (Table 2C ). Of note, there was no difference in VLST between the Ca and non-Ca groups.
Though recent guidelines have supported a shift towards a shorter duration of DAPT [40] , our findings on an increased late ST rate in Ca lesions may suggest that a longer duration of DAPT may still be necessary if BRS is to be implanted before the patient is to derive the potential benefits of BRS resorption. In our study, data on the use of dual antiplatelets therapy (DAPT) were available in the 395 patients whose follow up were available. All patients were prescribed aspirin during the duration of the study. Second generation P2Y 12 antiplatelet medications were used; clopidogrel (n = 157, 39.7%), prasugrel (n = 187, 47.3%) and ticagrelor (n = 51, 12.9%). The median duration of DAPT was 365.00 (IQR 364.00-394.50) days and was similar between the 2 groups. In a study to evaluate the impact of DAPT termination on late and very late ST in patients treated with the Absorb BRS, the incidence of ST was low while on DAPT but potentially higher when DAPT was terminated before 18 months [41, 42] . Further studies may be required to evaluate the effect of a prolonged duration of DAPT on the rate of late ST.
The findings showing a lesser acute lumen gain and similar 2 year MACE were consistent with previous research involving metallic DES in calcified versus non calcified lesions [8] . Moussa et al. reported in a subanalysis of the TAXUS IV trial [8] a significant reduction in late lumen loss in calcific lesions (n = 247) treated with PES vs BMS (0.26 ± 0.56 vs 0.51 ± 0.48 mm, p = 0.015). In a study from the SPIRIT II trial by Onuma et al. [43] , the efficacy of EES in patients with at least one angiographically defined moderate calcific lesion (68 patients), was compared to those without any calcific lesion (144 patients). Late lumen loss was similar between the two groups at two years. No significant difference in two-year MACE rates was observed between the two groups (calcific vs non-calcific: 10.9% vs 4.4%, p = 0.12). The numerically increased MACE rate was attributed to an increased ischemia-driven TLR (7.8% vs 1.5%, p = 0.03). However TLR rates were similar between the Ca and non Ca groups in our study.
In summary, clinical outcomes of calcified and non-calcified lesions treated with BRS are in general similar except for late ST. Overall twoyear MACE rates appear acceptable in patients with and without calcific lesions treated with BRS. Further larger randomized controlled trials comparing clinical outcomes of DES to BRS in calcified lesions may be required to evaluate the full impact of calcium on BRS outcomes compared to DES.
Study limitations
This is a single-center, single-arm registry with no direct comparison with metallic DES. The total number of patients in this study was still limited. In addition, calcification assessment was based on angiographic classification alone rather than characterization of coronary calcification using alternative imaging modality such as intravascular ultrasound. Thus, these findings warrant further confirmation in a large-scale trial. Furthermore, deciding which patient or lesion was suitable for treatment with BRS could have resulted in selection bias. The event rate is unknown in the patients (n = 60, 13.2%) who did not agree to participate in further follow up and hence excluded from clinical outcome analysis. We further evaluated the population who did not agree to further follow up and compared the baseline demographic, lesion and procedural characteristics between the cases with calcified lesions and non-calcified lesions. There were significant differences in terms of age and use of predilation between the 2 groups which were similarly observed in the main population. Overall, the results are similar which provide support to our inference that the clinical outcomes reported in our study may be extrapolated to the patients whose clinical outcomes were not available. In addition, as our study was not powered to study clinical outcomes in relation to DAPT, we believe that further studies may be required to evaluate if a prolonged duration of DAPT may reduce late onset ST in calcified lesions.
Conclusion
Careful more elaborate lesion preparation and the use of dedicated devices, such as scoring balloons and rotational atherectomy and intracoronary imaging were more likely encountered in Ca lesions. Even after more lesion preparation, acute gain and resulting final MLD by BRS implantation was less compared to non-calcified lesion. Clinical outcomes of calcified and non-calcified lesions treated with BRS were otherwise similar. However this is accomplished in the setting of appropriate case selection, adequate lesion preparation and scaffold optimization with attention to an adequate duration of dual antiplatelet in line with guideline recommendations. Interestingly, a different pattern of timing of ST was observed with no early ST but an increased late ST rate when implanted in calcified lesions. To account for baseline differences between patients with at least 1 moderately or heavily calcified lesion (Ca) and patients with no/mild calcified lesions (non-Ca), covariate adjustment using fourteen patient and lesion factors were used (see Online Supplement).
a Adjusted for gender, age, presentation with ACS, multivessel disease, diabetes mellitus, dyslipidemia, smoking, hypertension, peripheral artery disease, small vessel, bifurcation, average scaffold diameter per patient, total scaffold length per patient. DOCE: device oriented composite endpoints (composite of cardiac death, target vessel myocardial infarct and clinically indicated target lesion revascularization); POCE: patient oriented composite endpoints (composite of all -cause mortality, all cause myocardial infarct and any revascularization). (Number of composite endpoints does not add up as any patient may have multiple events.) Ca -calcified lesions; non-Ca -non calcified lesions; MACEmajor adverse cardiovascular events; MI -myocardial infarct; TLR -target lesion revascularization; TVR -target vessel revascularization; ST -scaffold thrombosis.
Clinical perspectives
Data on the impact of calcium (Ca) on outcomes in patients with lesions treated with bioresorbable vascular scaffolds (BRS) is limited, particularly in a "real world" study population. Careful more elaborate lesion preparation and the use of dedicated devices, such as scoring balloons and rotational atherectomy and intracoronary imaging were more likely encountered in Ca lesions. Late ST was more frequent in the Ca group compared to non-Ca group and no difference for VLST was observed. The findings merit further evaluation of clinical outcomes of BRS and the impact of implantation techniques in complex calcified lesions.
Supplementary data to this article can be found online at https://doi. org/10.1016/j.ijcard.2017.08.046.
